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Abstract
Background: Preclinical and clinical studies have shown that salmon calcitonin has cartilage protective effects in
joint degenerative diseases, such as osteoarthritis (OA). However, the presence of the calcitonin receptor (CTR) in
articular cartilage chondrocytes is yet to be identified. In this study, we sought to further investigate the expression
of the CTR in naïve human OA articular chondrocytes to gain further confirmation of the existents of the CTR in
articular cartilage.
Methods: Total RNA was purified from primary chondrocytes from articular cartilage biopsies from four OA
patients undergoing total knee replacement. High quality cDNA was produced using a dedicated reverse
transcription polymerase chain reaction (RT-PCR) protocol. From this a nested PCR assay amplifying the full coding
region of the CTR mRNA was completed. Western blotting and immunohistochemistry were used to characterize
CTR protein on protein level in chondrocytes.
Results: The full coding transcript of the CTR isoform 2 was identified in all four individuals. DNA sequencing
revealed a number of allelic variants of the gene including two potentially novel polymorphisms: a frame shift
mutation, +473del, producing a shorter form of the receptor protein, and a single nucleotide polymorphism in the
3’ non coding region of the transcript, +1443 C>T. A 53 kDa protein band, consistent with non-glycosylated CTR
isoform 2, was detected in chondrocytes with a similar size to that expressed in osteoclasts. Moreover the CTR was
identified in the plasma membrane and the chondrocyte lacuna of both primary chondrocytes and OA cartilage
section.
Conclusions: Human OA articular cartilage chondrocytes do indeed express the CTR, which makes the articular a
pharmacological target of salmon calcitonin. In addition, the results support previous findings suggesting that
calcitonin has a direct anabolic effect on articular cartilage.
Background
In vitro studies have shown that salmon calcitonin (sCT)
attenuates proteolysis in articular cartilage, inhibiting
collagenase and phospholipase A2 activities [1,2]. Simul-
taneous induction of the intracellular second messenger
cyclic adenosine 3’5’-monophosphate (cAMP) and
down-regulation of MMP has been observed in bovine
articular cartilage explants in response to sCT [3].
Moreover, sCT has been reported to induce anabolic
effects on cartilage formation, proteoglycan and glycosa-
minoglycan syntheses in chondrocytes and growth plate
cultures from different species [4-7]. In vivo,l o n g - t e r m
sCT treatment has been shown to increase the number
of hypertrophic chondrocytes and thickness of the epi-
physeal plate in young rats [8]. In addition, a number of
studies have documented the palliative effects of CT in
different joint damage animal models [9-12]. Finally, the
effect of sCT on cartilage degradation and pain allevia-
tion was recently demonstrated in different clinical set-
tings where osteoarthritis (OA) patients were treated
with salmon calcitonin [13,14]. Thus there are several
indications that modulation of the calcitonin receptor
(CTR) is a valid target for treatment of joint degenera-
tive diseases. However, the mode of action of which
sCT exerts its effect on cartilage need to be further
investigated.
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mediated through high-affinity CT receptors (CTR) - a
class B of the G-protein coupled receptor (GPCR)
family. The binding of sCT to its receptor produces
intracellular accumulation of cAMP [15]. The CTR has
been cloned and partially characterized in different cell
t y p e sa n ds p e c i e s[ 1 6 - 1 8 ] ,a n dan u m b e ro fC T Ri s o -
forms have been identified so far. In humans, CTR iso-
forms are known to arise from alternative splicing of the
p r i m a r yt r a n s c r i p t[ 1 9 , 2 0 ]o fau n i q u eg e n e( C A L C R )
located at chromosome 7q21.3 [21]. The two most com-
mon human variants differ in a 16-amino acid insert in
the putative first intracellular loop [22,23] and this fea-
ture confers them different abilities to activate the
cAMP and protein kinase C (PKC) signal transduction
pathways [24,25]. A different splice variant lacking both
the 16-amino acid insert in the first intracellular domain
as well as the first 47 amino acids of the amino-termi-
nus extracellular domain was reported to bind to [
125I]
sCT with high affinity and responding to human CT
with increases in cAMP [26]. The significance of two
most recently discovered isoforms [27] is still unknown.
A further human CTR variant results from a T-to-C
base mutation producing a leucine 447 to proline
(L447P) amino acid change. This substitution has no
apparent effect on ligand binding or receptor function
in vitro [28], but has been associated with decreased
fracture risk in postmenopausal women in different stu-
dies [29,30]. In summary, CTR variants appear to pre-
sent different binding properties and ability to couple to
signal transduction pathways. Currently, the occurrence,
expression regulation and physiological significance of
those variants are largely unknown.
The effects of sCT on bone have been demonstrated
to be mediated by direct binding of the hormone to
CTRs expressed by osteoclasts in their basolateral mem-
brane [31]. In contrast, no conclusive evidence of the
expression of the CTR in cartilage has been provided
yet. Our group has previously reported the existence of
an intron spanning sequence of the coding region of
CALCR mRNA in bovine articular cartilage [32]. In con-
trast, Lin and colleagues concluded that the CTR is not
expressed in human cartilage after investigating its exis-
tence in chondrocytes cultures by polymerase chain
reaction (PCR), western blotting and immunochemical
analysis [33]. This controversy has left an important
question unanswered: does the effect of sCT on articular
cartilage occur via a direct interaction with cartilage
cells or through an indirect route via inhibition of
resorptive activity of osteoclasts in subchondral bone?
In the present study we attempted to test the hypoth-
esis that the CTR is expressed in human articular carti-
lage. We used a specific RT-PCR DNA sequencing
strategy to retrieve and identify the CTR transcript
expressed in chondrocytes. We then sought to assess
the expression and identity of a CTR protein consistent
with the identified transcripts by western blotting and to
determine its subcellular localization by immunochem-
ical analysis.
Methods
Patients’ characteristics
This investigation originally included 21 OA patients (17
females and 4 males) with an average age of 66 ± 11
years undergoing elective total knee joint replacement
surgery at the Orthopedic Surgery Unit of Gentofte hos-
pital (Denmark). Given the characteristics of the study
samples and the molecular methods performed, indivi-
dual samples could not be used for simultaneous genetic
and protein analysis. Therefore, results presented in this
paper correspond to four patients of the study group in
which complete DNA sequencing could be optimally
performed. Four other patients were used for western
blotting analysis, and two different patients for immuno-
chemical analysis. The study was approved by the Ethics
Committee of the Capital Region of Denmark, DK-3400
(approval no. HD-2007-0084). Patients were informed
about the purpose of the study and gave written
consent.
Chondrocytes isolation from fresh human cartilage tissue
Articular cartilage from non-eroded areas with a normal
smooth surface and hard texture was isolated and used
for experiments. Dissected specimens free of bone tissue
were collected in DMEM (Lonza, Basel, Switzerland)
and preserved at 4°C until shipment to the laboratory
within 24 hours following surgery, then washed in Dul-
becco’s PBS buffer (Lonza) and used immediately for
chondrocyte cells isolation. Cartilage was cut in 1 mm
2
pieces and sequentially digested with 0.5% pronase
(Sigma-Aldrich, Dorset, UK) for one hour and 0.5% col-
lagenase type 2 (Wako, Osaka, Japan) overnight at 37°C.
The presence of viable chondrocytes was assessed by
microscopic observation. Cell pellets were directly used
for RNA isolation, western blotting or immunocyto-
chemical analysis or, alternatively, snap frozen in liquid
nitrogen and stored at -70°C for later use.
RNA extraction from isolated chondrocytes
After careful optimization of the RNA extraction from
cartilage procedure, then RNA was isolated from four
different patients. Cell lysis and RNA extraction were
performed using the High-Pure RNA Isolation kit and
reagents (Roche, Basel, Switzerland) following manufac-
turer’si n s t r u c t i o n s .S i xt o2 5μg of high quality RNA
w a so b t a i n e df r o ma na v e r a g eof 6 million cells, resus-
pended in 200 μL of PBS and lysed in 400 μLo fl y s i s /
binding buffer during 20 min of incubation on ice and
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fer (10 mM Tris-Cl, pH 8.5). RNA integrity, quality and
quantity were assessed using an Agilent 2100 Bioanaly-
zer (Agilent Technologies, Santa Clara, CA, USA).
Reverse transcription polymerase chain reaction
Complementary DNA (cDNA) copies of chondrocyte
RNA were prepared using the Transcriptor First Strand
cDNA Synthesis kit (Roche). One microgram samples of
high quality RNA (RNA Integrity Number (RIN) > 8,
concentration > 50 ng/μL, no strong secondary peaks in
the electropherogram, A260/280 > 1.8) were used as
template in single cDNA synthesis reactions. Combined
random hexamer plus anchored-oligo(dT)18 primers
were used in a pre-reaction mix containing RNA tem-
plate and primers were first heat denatured for 10 min
at 65°C. Subsequently, a preincubation step at 25°C for
10 minutes was introduced before the reverse transcrip-
tion reaction was performed at 50°C for 1 hour. RT-
PCR negative controls were carried out in parallel by
substituting reverse transcriptase with water.
CTR polymerase chain reaction assay
The NCBI Reference Sequence NM_001742.2 was used as
template for CALCR PCR assays design. A nested PCR
strategy was adopted to amplify the entire coding region
of the CTR with specificity and high reaction yields.
Briefly, primers (Eurofins MWG Operon, Ebersberg, Ger-
many) for the primary amplification from 2 μLo fc D N A
preparation were CALCR_F (5’-CCAGTGACAGAATTC-
CAGGAC, sense) and CALCR_R (5’-GTCTCCCAAAG-
CAACAGTACC, antisense). Nested primers CALCR_NF
(5’-CCAGGACAAAGAGATCTTCA, sense) and
CALCR_NR (5’-CAGGAAATGATGGCTCAGTG, anti-
sense) were used to amplify an internal target from 2 μL
of the primary amplification product. Herculase II Fusion
DNA polymerase (Stratagene, La Jolla, CA, USA) was used
in those long range PCR experiments. PCR amplifications
were performed in a DYAD dual block PCR machine (MJ
Research, Waltham, MA, USA) and consisted of 35 cycles
of: 2 minutes denaturation at 95°C; 20 seconds annealing
at 54°C for CALCR_NF/CALCR_NR and at 53°C for
CALCR_F/CALCR_R; 49 seconds extension at 72°C for
CALCR_NF/CALCR_NR and at 50 seconds for
CALCR_F/CALCR_R. Negative controls were matched to
all samples amplified. Negative control reactions to detect
genomic and pseudogene DNA amplification were per-
formed by omitting reverse transcriptase in RT-PCR reac-
tions. Negative controls for laboratory contamination were
performed using water as template in PCR reactions.
DNA sequencing of nested PCR products
DNA sequencing was performed in samples of patient
cDNA amplified by nested PCR. The 1500 bp amplicon
generated by the CALCR_NF/CALCR_NR assay was
purified from the PCR reaction using the QIAquick
PCR purification Kit (Qiagen, Hilden, Germany).
Approximately 30-60 ng of purified products were
sequenced using Bigdye Terminator chemistry in ABI
3730XL capillary sequencers (Applied Biosystems, Foster
City, CA, USA) at Eurofins MWG Operon. Overlapping
sequencing primers were designed in the 147-1647
nucleotide region of NM_001742.2 using Eurofins
MWG Operon online tool. Primers covered both DNA
strands of the nested PCR product aiming at excluding
polymerase-mediated DNA sequence changes during
PCR. For those samples showing polymorphisms or
mutations a second confirmatory DNA sequencing
experiment was performed starting from stored cDNA
material of the patient.
Western blotting analysis
Chondrocyte pellets of about 6 million of cells were
homogenized in 50 μL of RIPA buffer (140 mM NaCl,
10 mM Tris, pH 8, 1 mM EDTA, 1% Triton X-100,
0.1% SDS, 0.1% deoxycholic acid) containing Complete
mini EDTA-free protease inhibitor cocktail (Roche) and
incubated for 5 min on ice. Human osteoclasts were dif-
ferentiated for 12 days from CD14+ monocytes purified
from human blood (Rigshospitalet Bloodbank, Copenha-
gen, Denmark) using Receptor Activator for Nuclear
Factor B Ligand and Macrophage colony-stimulating
factor as previously described [34]. Pellets were lysed in
500 μL RIPA buffer. Ten to 20 μg total protein of each
lysate preparation was electrophoresed in polyacrylamide
gels in denaturating condition (10% dithiothreitol) with
Full Range Rainbow protein marker (GE Healthcare,
Buckinghamshire, UK). Proteins were blotted on nitro-
cellulose membranes (Whatman, Kent, UK), soaked in
10 mM N-cyclohexyl-3-aminopropanesulfonic acid
(Sigma) plus 10% ethanol pH 11, and incubated for 1
hour in blocking buffer (TBS 0.1% Tween-20 + 5%
skimmed milk powder). Nitrocellulose membranes were
probed for 2 hours with primary antibodies at different
dilutions in blocking buffer. After blocking, membranes
were probed for 2 hours with anti-human CTR antibo-
dies from different suppliers: SP1338P (Acris, Herford,
Germany) diluted 1:200; H00000799-M01 (Abnova, Tai-
pei City, Taiwan) diluted 1:200, 250618 (Abbiotec, San
Diego, CA, USA) diluted 1:200 and Ab11042-50
( A b c a m ,C a m b r i d g e ,M A ,U S A )d i l u t e d1 : 2 0 0 0 .S u b s e -
quently, membranes were incubated for one hour at
room temperature with secondary antibody, either rabbit
anti-mouse 315035045 or goat anti-rabbit 111035003
(The Jackson Laboratory, Bar Harbor, ME, USA) diluted
1:10000. The Pierce ECL western blotting substrate
(Thermo Fisher Scientific, Waltham, MA, USA) was
used for detection and activated membranes were
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care) autoradiography films.
Immunochemical localization of the human CTR
Primary chondrocytes were isolated from cartilage as
described above. The cells were fixed in 4% formalin (Lil-
lie’s fluid, Sigma-Aldrich, Glostrup, Denmark) for 10 min-
utes and rinsed in PBS. Endogenous peroxidases were
blocked with 1% hydrogen peroxide in PBS for 20 minutes,
followed by rinsing in TBS (Tris buffer saline). Next the
cells were incubated with a rabbit polyclonal antibody
raised against CTR (SP1338P, Acris antibodies, Herford,
Germany), diluted 1:500 and incubated for 1 hour, includ-
ing blocking agent (BSA, Sigma-Aldrich, Roedovre, Den-
mark). After rinsing in TBS, 5 drops of peroxidase-labeled
EnVision+ anti-rabbit (Dako, Roedovre, Denmark) was
added and incubated for 30 minutes. The cells were then
rinsed and Dako DAB+ chromogen was add and the color
reaction was stopped after 5 minutes, by rinsing in milli-Q
water. The cells were counterstained in Mayer’s Hematox-
ylin for 1 minute, rinsed in tap water and ethanol. The
stained cells were smeared on to a slide and covered with
cover glass. Before isolation of the primary cells from car-
tilage, small pieces of the tissue were separated and fixed
overnight in 4% formalin. The tissues were then embedded
i np a r a f f i na n dc u ti n5m i c r o m eter sections. They were
then deparaffinated, endogenous peroxidase activity was
blocked in 0.4% H2O2 in 99% ethanol and samples were
rehydrated and unmasked for 2 hours in citrate buffer, pH
6 at 60°C. The sections were then incubated overnight at
4°C with polyclonal antibody diluted 1:100 in 1% casein
blocking agent (Sigma-Aldrich, Roedovre, Denmark). Sec-
tions were then rinsed and peroxidase-labeled EnVision+
anti-rabbit (Dako, Roedovre, Denmark) was added and
incubated for 30 minutes. The sections were then rinsed,
Dako DAB+ chromogen was added and the color reaction
was stopped after 10 minutes by rinsing in Milli-Q water.
Finally, sections were counterstained in Mayer’sH e m a t o x -
ylin for 20 seconds, rinsed in tap water, dehydrated,
mounted in Kaiser’s glycerin jelly and covered. Both pri-
mary cells and cartilage sections were assessed under the
microscope using CellA v2.7 software (Olympus, Ballerup,
Denmark).
Results
Human chondrocytes express isoform 2 of the CTR
Chondrocytes isolated by enzymatic digestion were used
to obtain high quality cartilage RNA for RT-PCR analy-
sis, which was converted to cDNA. The nested PCR
reaction (1:CALCR_F/CALCR_R; 2:CALCR_NF/
CALCR_NR) produced nanogram amounts of a single
1.5 kbp amplicon. Purification and sequencing of this
band confirmed the presence of the full coding sequence
of the CALCR isoform 2 in the four patients included.
The sequences have been annotated and deposited at
the INSDC nucleotide database (accession numbers
FN994993 to FN994996). A number of signature poly-
morphisms were observed in sequencing electrophero-
grams of those transcripts. Remarkably, FN994993
presented a heterozygous nonsense mutation at nt +473,
upstream of the start codon (Figure 1A). A traceable n
+1 secondary reading frame, denoting the presence of
two distinct mRNA species, can be seen starting from
the deleted T nucleotide. Three different C-to-T single
nucleotide polymorphisms (SNP) were also found at
positions -6, +1340, +1443 (Figure 1B).
Chondrocytes synthesize a 53 kDa CTR protein consistent
with isoform 2 of the CTR
A panel of anti-CTR antibodies from different providers
was tested in osteoclasts lysates to identify consensus
immunoreactive band(s) attributable to the CTR. Four
antibodies detected a 53 kDa band consistent with the
molecular weight of the osteoclast CTR (Figure 2A).
Western blots of parallel samples of chondrocytes and
osteoclasts lysates retrieved the same 53 kDa band in
both cell types. CTR levels in chondrocytes were lower
for the same amount of total protein loaded (Figure 2B).
Subsequent analysis of fresh chondrocyte preparations
demonstrated the presence of sizeable amounts of CTR
protein in those cells (Figure 2C).
The CTR protein is localized the plasma membrane of
primary chondrocytes
The expression of the CTR was further investigated by
immunohistochemistry. Immunoreactivity was observed
i nt h ep l a s m am e m b r a n eo fp r o l i f e r a t i v ec h o n d r o c y t e s
close to the articular surface (Figure 3A, B and 3C). The
s t a i n i n gw a ss e e na sad a r kb r o w nr i n gf o l l o w i n gt h e
cellular membrane. Similar staining was observed for
primary chondrocytes, although the signal was also
observed in the cytosol (Figure 3D). The cytosol staining
was probably due the fact that the cell membrane has
been permeabilized when isolated from the extracellular
matrix by the detergents added. In many instances the
cell surface was ruffled and due to the harsh handling of
the tissue. Staining using isotype antibody control was
negative (Figure 3E). Osteoclasts, isolated with magnetic
beads (seen as round spots) and grown on bones slices,
were used as positive controls (Figure 3F). Immunoreac-
tivity was observed intracellularly in this multinuclei
cell. The osteoclast was seated in a resorption pit; thus
the surrounding bone becomes unfocused. No-antibody
control was negative (data not shown).
Discussion
The results presented here are the strongest evidences
published to date of the expression of calcitonin
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assay developed in this study led to the sequencing of
the full coding sequence of CALCR gene transcripts of
cartilage of OA patients. The CTR isoform 2 was consis-
tently found in all four patients examined. By aligning
experimental data to the NCBI Reference Sequence
NM_001742.2, a number of genetic features became
a p p a r e n t .W ec o n f i r m e dt h ep r e s e n c eo ft w of r e q u e n t
polymorphisms at positions -6 C>T and +1340 C>T.
The former has been previously reported but not asso-
ciated with any particular phenotype [35], while the
later provokes a change in amino acid in the CTR pro-
tein, L447P that has been linked to bone mineral density
(BMD) and osteoporosis (OP). In particular, heterozyg-
osity at L447P has been linked to higher BMD at the
femoral neck [36].
Interestingly, three patients in our study were hetero-
zygous for L447P. Restriction fragment length poly-
morphism analysis of Japanese patients previouly
identified this CALCR polymorphism as arising from a
single nucleotide substitution leading to either a proline
(CC phenotype), leucine (TT) or heterozygote (TC) gen-
otype at amino acid position 447 [37]. Similar studies
have been performed in different population such as
postmenopausal Italian [38], Caucasian [39] and Polish
[40] women, as well as in Caucasians, African-Ameri-
cans, Asians and Hispanics [41] in order to assess the
prevalence of those genotypes and investigate their
potential association to BMD. While their authors
extract different conclusions, these studies taken
together suggest that the human CALCR gene plays a
role in BMD and, ultimately, in the incidence of OP.
A novel polymorphism was found at nt +1443 C>T in
the 3’ untranslated region of the CALCR mRNA. The
region contains regulatory sequences targeted by tran-
scription factors, but the effect of such nucleotide
change in the expression of the transcript is unknown.
The most dramatic finding in the transcript sequences
analyzed was a heterozygous missense mutation at posi-
tion nt +473 caused by the deletion of a T base. This
mutation provokes a frame shift in protein translation at
amino acid residue 158 leading to early termination at
residue 162, located in the first trans-membrane region
of the receptor. It would be of interest to study the
effect of such mutation and determine its cellular phe-
notype. Incidentally, a recent genetic association study
concluded that a CA dinucleotide polymorphism in the
calcitonin gene (CALCA) is associated with risk of
Figure 1 Allelic variants of CTR isoform 2 found in human chondrocytes. (A) A novel CALCR frameshift mutation was found in an OA
patient. Electropherogram showing a heterozygous single nucleotide deletion at position +473 in CALCR cDNA amplified from primary
chondrocytes. Note the appearance of a +1 frameshift in one of the alleles after nt +473. (B) Electropherograms showing the presence of CALCR
single nucleotide polymorphisms in four different patients. Three C>T transitions were found at previously reported positions nt -6 (5’-UTR
region) and +1340 (coding sequence), and unreported position nt +1443 (3’-UTR region). The complete sequences have been deposited at the
INSDC nucleotide database (accession numbers FN994993 to FN994996).
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system is deeply involved in cartilage health [42].
In an initial screening we found a common band of
approximately 53 kDa in osteoclasts lysates detected by
different antibodies. This same band was also retrieved
in chondrocytes. The theoretical molecular weight of
the mature protein produced by isoform 2, based on its
amino acid sequence, is 55 kDa. Four putative N-glyco-
sylation sites, i.e. N28, N73, N125 and N130 are present
in the amino terminal extracellular domain of the
human CTR (UniProtKB/Swiss-Prot P30988). The wes-
tern blot presented here, performed on freshly isolated
chondrocyte pellets, showed a high molecular weight
material smear above the 53 kDa bands, but most of the
immunoreactivity appears as a single discrete band (Fig-
ure 2C). This would suggest that those glycosylation
sites are not modified neither in human chondrocytes
nor osteoclasts, in contrast to previous findings in het-
erologous expression studies of human CTR in monkey
kidney COS-1 cells [43]. This same blot shows that
chondrocytes are indeed capable of strong expression of
CTR protein. Paradoxically,t h i ss t r o n ge x p r e s s i o nw a s
demonstrated using the same antibody used by Lin and
coworkers [44]. The definitive confirmation of the
expression of the CTR protein in human chondrocytes
could be obtained by combined immunoprecipitation
and mass spectrometry, but it was out of the scope of
this study. These results were supported by the
localization of the receptor to articular chondrocytes in
cartilage sections from OA patients. Next it would be
interesting to investigate to what degree different chon-
drocyte subpopulations express different amounts of
CTR and whether the CTR is associated with other phe-
notype-specific proteins.
The results presented here allow us to conclude that
human cartilage does express the calcitonin receptor.
The main reason why other studies failed to find similar
results may be the cell phenotype used in those investi-
gations. The study published by Lin and coworkers was
performed using cultured chondrocytes [45]. Other
authors have provided evidences that culturing chondro-
cytes as an adherent monolayer invariably leads to a
process of dedifferentiation whereby cells adopt a fibro-
blastic morphology, lose their chondrocyte-specific gene
expression pattern and initiate or upregulate the expres-
sion of fibroblast-associated genes such as type I, III and
V collagens and versican [46-48]. Therefore, chondro-
cytes dedifferentiated on plastic with fetal bovine serum
is not recommendable as a representative system for
cartilage cell biology studies, particularly in regards to
gene expression profile.
Conclusions
As mentioned above, there are clear evidences of the
beneficial effects of calcitonin in OA. However, its mode
of action has not been yet fully clarified. OA is a
Figure 2 Western blot detection of CTR in human chondrocytes. (A) Screening of a panel of anti-CTR antibodies against human osteoclast
lysates. A 53 kDa band (arrow), consistent with the receptor’s molecular weight, was chosen to evaluate antibody performance. Ab1: H00000799-
M01 diluted 1:200; Ab2: SP1338P dil. 1:200; Ab3: 250618 dil. 1:200; Ab4: Ab11042-50 dil. 1:2000. (B) Simultaneous detection of the 53 kDa CTR
band in human osteoclasts and chondrocytes OCL: 10 μg and 20 μg protein of in vitro differentiated human osteoclasts lysates [34]; CHO1: 30
μg and 15 μg protein of chondrocytes lysates from the same individual; CHO2: 30 μg and 15 μg protein of chondrocytes lysates from a second
individual. Antibody: Ab3, dil. 1:200. (C) Detection of CTR in 20 μg protein cell lysates samples of freshly isolated chondrocyte from two different
individuals. Antibody: Ab4, dil. 1:2000.
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Our results suggest that, beyond an indirect effect on
cartilage via subchondral bone turnover [49], calcitonin
may directly target chondrocytes in articular cartilage.
Human cartilage cells do express the CTR. This will be
confirmed in future clinical studies including a larger
number of patients. The identification of isoform 2 in
OA human cartilage allows for more targeted pharma-
cological investigations into the mode of action of calci-
tonin in OA treatment and prevention. Further research
is also warranted into the intracellular mechanisms by
which calcitonin protects chondrocytes, increases extra-
cellular matrix synthesis and inhibits cartilage
degradation.
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